11.20
+0.99%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Simcere Pharmaceutical Group
Its shares trade on HKEX under the ticker 2096.HK. It has been listed since 27 October 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥9.00bn and net income of CN¥1.56bn. At that date it held total assets of CN¥17.15bn and shareholders' equity of CN¥10.96bn.
Simcere Pharmaceutical Group Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2020-10-27. The firm's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The firm also produces innovative drugs, such as Endostar used for oncology. The firm is also involved in providing promotion services for third-party drugs sold by medical institutions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 27 Oct 2020
- Employees
- 7,661
- Website
- simcere.com ↗
Leadership
Pay as last reported
- Mr. Jinsheng RenExecutive Chairman of the Board, Chief Executive Officer, FounderCN¥1.9m
- Mr. Yushan WanChief Financial Officer, Executive Director, Joint Company Secretary, since 2022CN¥6.8m
- Mr. Danny ChenSenior Vice President
- Mr. Kevin OliverSenior Vice President
- Mr. Tong ZhuSenior Vice President
- Mr. Gaobo ZhouChief Investment Officer
- Mr. Xianghua ChengVice President
- Mr. Ruiwen ShiVice President
- Mr. Feng WangVice President
- Mr. Renhong TangExecutive Director, since 2022CN¥10.5m
- Ms. Xi WangExecutive Director, since 2023
- Mr. Mookerjee BijoyeshChief Medical Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Simcere's generic drugs like Bicun for central nervous system diseases are widely used in China.
- Endostar, an innovative oncology drug, is a key product in Simcere's portfolio.
- The company's 7,661 employees support comprehensive pharmaceutical R&D and manufacturing.
Weaknesses
- Simcere's reliance on generic drugs may limit growth in high-margin markets.
- The firm's focus on China may restrict international expansion opportunities.
- Dependence on specific products like Jepaso and Jiebaili could pose risks.
Opportunities
- Expanding oncology drug offerings with Endostar could capture more market share.
- Growing demand for autoimmune disease treatments like Yingtaiqing in China.
- Increasing third-party drug promotion services for medical institutions in China.
Threats
- Intense competition in the Chinese pharmaceutical market for generic drugs.
- Regulatory changes affecting oncology drug approvals in China.
- Economic downturns impacting healthcare spending in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.